Skip Navigation


European Heart Journal Advance Access originally published online on November 10, 2006
European Heart Journal 2006 27(24):2911-2913; doi:10.1093/eurheartj/ehl352
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/24/2911    most recent
ehl352v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Leone, A. M.
Right arrow Articles by Crea, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leone, A. M.
Right arrow Articles by Crea, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Stem cells in acute myocardial infarction: the good, the bad, and the ugly

Antonio Maria Leone and Filippo Crea*

Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168 Roma, Italy

* Corresponding author. Tel: +39 630154187; fax: +39 63055535. E-mail address: filippo.crea@rm.unicatt.it

This editorial refers to ‘Intracoronary infusion of progenitor cells is not associated with aggravated restenosis development or atherosclerotic disease progression in patients with acute myocardial infarction’{dagger} by B. Assmus et al., on page 2989

The first 150 words of the full text of this article appear below.

Any new form of treatment, when based on solid experimental observations, initially generates a lot of enthusiasm among researchers as well as among patients (when media get involved). If the initial positive results in observational studies are then confirmed in small randomized trials with surrogate endpoints and finally in large randomized trials with clinical endpoints, the new treatment gains momentum and becomes common practice when incorporated in guidelines (for instance, the use of ACE inhibitors in patients with heart failure). At the other extreme, if the initial positive results are not confirmed in controlled randomized trials, the new treatment is quickly forgotten (for instance, the use of positive inotropic agents in patients with heart failure). As clinicians, we know, however, that we have to accept the grey area where things can remain uncertain for years or even decades. A good example is offered by lipid-lowering drugs: in spite of compelling . . . [Full Text of this Article]

The good
The bad

The ugly


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Intracoronary infusion of progenitor cells is not associated with aggravated restenosis development or atherosclerotic disease progression in patients with acute myocardial infarction
Birgit Assmus, Dirk H. Walter, Ralf Lehmann, Jörg Honold, Hans Martin, Stefanie Dimmeler, Andreas M. Zeiher, and Volker Schächinger
EHJ 2006 27: 2989-2995. [Abstract] [Full Text]